HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sunscreen labeling

This article was originally published in The Rose Sheet

Executive Summary

Sun care manufacturers will need "sufficient" time to comply with labeling requirements under the OTC drug facts final rule, the Cosmetic, Toiletry and Fragrance Association notes in comments submitted to FDA Dec. 2. "The process of reformatting and redesigning labels to implement requirements of the drug facts rule as it applies to OTC sunscreen drug products will be a lengthy undertaking," the association adds, noting its support for the delayed implementtation. FDA requested comments from stakeholders on its decision to postpone the May 16, 2005 implementation date of the drug facts for OTC sunscreen drug products in Sept. 3 Federal Register notice (1"The Rose Sheet" Sept. 6, 2004, p. 5)...
Advertisement

Related Content

Sunscreen Drug Facts Implementation Delayed To Coincide With FM
Sunscreen Drug Facts Implementation Delayed To Coincide With FM
Advertisement
UsernamePublicRestriction

Register

RS012677

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel